InvestSMART

Zelira Therapeutics Limited (ASX: ZLD) - Announcements

- Current share price for ZLD : $0.500

ASX company news and announcements for Zelira Therapeutics Limited (ZLD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Zelira Therapeutics Limited (ZLD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Zelira Therapeutics Limited (ZLD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Zelira Therapeutics Limited (ZLD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Chairman Loan 15 Jun 2026 2:11PM $0.500 $0.500 fallen by 0%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 12:14PM $0.500 $0.500 fallen by 0%
$6 Director Loan 10 Mar 2026 2:28PM $0.500 $0.500 fallen by 0%
$6 Suspension from Quotation 2 Mar 2026 9:38AM $0.500 $0.500 fallen by 0%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jan 2026 9:25AM $0.680 $0.500 fallen by 26.47%
$6 Transformative US$33M Fundraising into Zeliras HOPE 1 SPV 16 Jan 2026 10:03AM $0.360 $0.500 risen by 38.89%
$6 Change of Director's Interest Notice x2 4 Dec 2025 8:06PM $0.350 $0.500 risen by 42.86%
$6 Notification regarding unquoted securities - ZLD 4 Dec 2025 8:03PM $0.350 $0.500 risen by 42.86%
$6 Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund 25 Nov 2025 2:33PM $0.340 $0.500 risen by 47.06%
$6 Proposed issue of securities - ZLD 19 Nov 2025 3:27PM $0.375 $0.500 risen by 33.33%
$6 Results of Meeting 19 Nov 2025 2:40PM $0.375 $0.500 risen by 33.33%
$6 2025 Annual General Meeting Presentation 19 Nov 2025 12:03PM $0.375 $0.500 risen by 33.33%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 27 Oct 2025 2:33PM $0.350 $0.500 risen by 42.86%
$6 Notification of cessation of securities - ZLD 22 Oct 2025 12:31PM $0.360 $0.500 risen by 38.89%
$6 Letter to Shareholders 20 Oct 2025 4:21PM $0.350 $0.500 risen by 42.86%
$6 Notice of Annual General Meeting/Proxy Form 20 Oct 2025 4:21PM $0.350 $0.500 risen by 42.86%
$6 Appendix 4G 26 Sep 2025 12:20PM $0.360 $0.500 risen by 38.89%
$6 Annual Report to shareholders 26 Sep 2025 12:19PM $0.360 $0.500 risen by 38.89%
$6 AGM Date and Closing Date for Director Nominations 23 Sep 2025 4:21PM $0.420 $0.500 risen by 19.05%
$6 Director Loans 16 Sep 2025 11:58AM $0.380 $0.500 risen by 31.58%
$6 Preliminary Final Report 29 Aug 2025 2:00PM $0.450 $0.500 risen by 11.11%
$6 Preliminary Final Report 29 Aug 2025 2:00PM $0.450 $0.500 risen by 11.11%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2025 4:29PM $0.410 $0.500 risen by 21.95%
$6 Zelira Therapeutics Secures R&D Loan Facility 24 Jul 2025 12:05PM $0.410 $0.500 risen by 21.95%
$6 Publication of ZLT-L-007 IRB Approved Observational Study 22 May 2025 8:21AM $0.495 $0.500 risen by 1.01%

1 - 25 of 541 results

Page 1 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.